JP2015520221A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520221A5
JP2015520221A5 JP2015517850A JP2015517850A JP2015520221A5 JP 2015520221 A5 JP2015520221 A5 JP 2015520221A5 JP 2015517850 A JP2015517850 A JP 2015517850A JP 2015517850 A JP2015517850 A JP 2015517850A JP 2015520221 A5 JP2015520221 A5 JP 2015520221A5
Authority
JP
Japan
Prior art keywords
disease
dementia
alzheimer
treating
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2013/051606 external-priority patent/WO2013190302A1/en
Publication of JP2015520221A publication Critical patent/JP2015520221A/ja
Publication of JP2015520221A5 publication Critical patent/JP2015520221A5/ja
Pending legal-status Critical Current

Links

JP2015517850A 2012-06-21 2013-06-20 カンシル酸塩 Pending JP2015520221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
US61/662,592 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018021595A Division JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Publications (2)

Publication Number Publication Date
JP2015520221A JP2015520221A (ja) 2015-07-16
JP2015520221A5 true JP2015520221A5 (enExample) 2016-08-12

Family

ID=48746084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015517850A Pending JP2015520221A (ja) 2012-06-21 2013-06-20 カンシル酸塩
JP2018021595A Active JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018021595A Active JP6509393B2 (ja) 2012-06-21 2018-02-09 カンシル酸塩

Country Status (42)

Country Link
US (1) US10548882B2 (enExample)
EP (2) EP3064494A1 (enExample)
JP (2) JP2015520221A (enExample)
KR (1) KR102123708B1 (enExample)
CN (2) CN106279102A (enExample)
AP (2) AP2017009693A0 (enExample)
AR (2) AR091495A1 (enExample)
AU (2) AU2013279109B2 (enExample)
BR (2) BR112014031531B1 (enExample)
CA (1) CA2875589C (enExample)
CL (1) CL2014003374A1 (enExample)
CO (1) CO7151486A2 (enExample)
CR (2) CR20140571A (enExample)
CY (1) CY1119505T1 (enExample)
DK (1) DK2864316T3 (enExample)
DO (1) DOP2014000268A (enExample)
EC (1) ECSP14032215A (enExample)
ES (1) ES2618939T3 (enExample)
HR (1) HRP20170359T1 (enExample)
HU (1) HUE033376T2 (enExample)
IL (1) IL236131A0 (enExample)
IN (1) IN2014DN10088A (enExample)
LT (1) LT2864316T (enExample)
MA (2) MA39259B1 (enExample)
ME (1) ME02633B (enExample)
MX (1) MX354214B (enExample)
NI (1) NI201400146A (enExample)
NZ (2) NZ702742A (enExample)
PE (1) PE20150670A1 (enExample)
PH (2) PH12014502803A1 (enExample)
PL (1) PL2864316T3 (enExample)
PT (1) PT2864316T (enExample)
RS (1) RS55815B1 (enExample)
RU (1) RU2638175C2 (enExample)
SG (1) SG11201407934UA (enExample)
SI (1) SI2864316T1 (enExample)
SM (1) SMT201700142T1 (enExample)
TN (1) TN2014000491A1 (enExample)
TW (2) TWI639591B (enExample)
UA (1) UA114196C2 (enExample)
WO (1) WO2013190302A1 (enExample)
ZA (1) ZA201500408B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
AR107783A1 (es) 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
US20190262327A1 (en) * 2016-03-15 2019-08-29 Astrazeneca Ab Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
CA3131753A1 (en) * 2019-03-14 2020-09-17 Astrazeneca Ab Lanabecestat for weight loss

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
JP4273406B2 (ja) 2001-06-01 2009-06-03 小野薬品工業株式会社 アルドース還元酵素阻害剤を有効成分とする脱髄性疾患または脱髄を伴う疾患治療剤
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
EP1729771B1 (en) 2004-03-22 2009-10-14 Eli Lilly & Company Pyridyl derivatives and their use as mglu5 receptor antagonists
RU2008100165A (ru) 2005-06-14 2009-07-20 Шеринг Корпорейшн (US) Ингибиторы аспартильных протеаз
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
WO2007076247A1 (en) 2005-12-21 2007-07-05 Boehringer Ingelheim International Gmbh Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
RU2009100074A (ru) 2006-06-12 2010-07-20 Шеринг Корпорейшн (US) Гетероциклические ингибиторы аспартильной протеазы
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
US20090325993A1 (en) 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
MX2009012177A (es) 2007-05-07 2009-11-23 Schering Corp Moduladores de gamma-secretasa.
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
AU2009277485B2 (en) 2008-07-28 2013-05-02 Eisai R&D Management Co., Ltd. Spiroaminodihydrothiazine derivatives
US8450308B2 (en) 2008-08-19 2013-05-28 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
EA201100461A1 (ru) 2008-09-11 2011-10-31 Амген Инк. Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
CN102348698B (zh) 2009-03-13 2015-06-03 生命医药公司 β-分泌酶的抑制剂
UY32751A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
TW201103893A (en) 2009-07-02 2011-02-01 Astrazeneca Ab New compounds
WO2011106414A1 (en) 2010-02-24 2011-09-01 Dillard Lawrence W Inhibitors of beta-secretase
WO2011123674A1 (en) 2010-03-31 2011-10-06 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
US8921363B2 (en) 2010-08-05 2014-12-30 Amgen Inc. Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
UY33627A (es) 2010-09-24 2013-04-30 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
WO2012071458A1 (en) 2010-11-22 2012-05-31 Array Biopharma Inc. Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
ES2566373T3 (es) 2011-10-10 2016-04-12 Astrazeneca Ab Inhibidores monofluoro beta-secretasa
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors

Similar Documents

Publication Publication Date Title
JP2015520221A5 (enExample)
JP2012508734A5 (enExample)
RU2014148305A (ru) Камсилатная соль
ME02728B (me) Jedinjenja i njihova upotreba kao bace inhibitori
JP2015500223A5 (enExample)
EA201190020A1 (ru) Производные изоиндола в качестве ингибиторов васе и их применение
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2011504474A5 (enExample)
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2019524822A5 (enExample)
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IL278188B2 (en) Sublingual formulation of riluzole
JP2016512817A5 (enExample)
HK1206350A1 (en) 2h-imidazol-4-amine compounds and their use as bace inhibitors
WO2012091593A8 (en) Granulates comprising eslicarbazepine acetate
HK1206348A1 (en) Cyclohexane-1,2'-indene-1',2"-imidazol compounds and their use as bace inhibitors
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
JP2013537901A5 (enExample)
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
JOP20190180A1 (ar) مشتق أوكسازين حر القاعدة في صورة بلورية
EP3085691A4 (en) Method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone, thus produced crystalline polymorph of the anhydrous form, use thereof for the treatment of alzheimer's disease, parkinsonism and other neurodegenerative disorders, and pharmaceutical composition
Wedzicha et al. D44 COPD: TREATMENT FROM BRONCHODILATORS TO OTHER PHARMACOLOGICAL INTERVENTIONS: Efficacy And Safety Of Qva149 Versus Glycopyrronium And Tiotropium In A Subgroup Of Patients With Severe COPD: The Spark Study
Gao Various toxicities: 2 case reports